Mixed anxiety–depressive disorder

BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Retrieved on: 
Thursday, March 28, 2024
Depression, Deep, Brainsway, Medicine, Safety, MDD, Patient, Ageing, TMS, Journal, Doctor of Philosophy, DSM-IV codes, Efficacy, Mixed anxiety–depressive disorder, Atrophy, Scalp, FDA, Pharmaceutical industry

The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD).

Key Points: 
  • The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD).
  • In the study, data was analyzed from 247 depression patients at 16 clinical sites in this age group who had been treated with BrainsWay’s proprietary H1 Coil.
  • The outcomes were comparable to those reported in a post-marketing analysis of over 1,350 patients published in 2023.
  • This can make it challenging for certain non-invasive technologies to reach the brain areas involved in depression,” said Colleen Hanlon, PhD, Vice President of Medical and Clinical Affairs at BrainsWay.

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 6, 2024
TMS, Parkinson's disease, Medicine, Mental health, Human, Traction, Growth, Stroke, Adjustment, Safety, DSM-IV codes, Tic disorder, Mixed anxiety–depressive disorder, Brainsway, Journal, Rehabilitation, Science, OCD, Transcranial magnetic stimulation

BURLINGTON, Mass. and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.

Key Points: 
  • and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.
  • Gross margin for the fourth quarter of 2023 was 75%, an increase from 71% in the fourth quarter of 2022, and an increase from 74% in the third quarter of 2023.
  • Net income for the fourth quarter of 2023 was $0.1 million, compared to a net loss of $3.9 million for the fourth quarter of 2022, and a loss of $0.2 million for the third quarter of 2023.
  • Adjusted EBITDA1 for the fourth quarter of 2023 was approximately $0.8 million, compared to a loss of $3.6 million for the fourth quarter of 2022, and positive Adjusted EBITDA1 of $0.3 million in the third quarter of 2023.

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

Retrieved on: 
Friday, January 26, 2024
Dana–Farber Cancer Institute, Artificial intelligence, Psychiatry, Research, Physics, Biotechnology, Partnership, Behavioural sciences, Deficit spending, Drug discovery, Mixed anxiety–depressive disorder, Neuropsychiatry, Bullfrog, Doctor of Philosophy, Radiology, Machine learning, Health informatics, Clinical trial, Ageing, Neurodegenerative disease, Growth, Medical device

“We are thrilled to welcome Dr. Smith and Dr. Wala to our advisory board,” said Vin Singh, CEO of BullFrog AI.

Key Points: 
  • “We are thrilled to welcome Dr. Smith and Dr. Wala to our advisory board,” said Vin Singh, CEO of BullFrog AI.
  • “I am honored to join the advisory board of BullFrog AI, a company that stands at the forefront of a transformative wave in the biopharma industry,” said Dr. Smith.
  • “BullFrog AI’s partnership with the Lieber Institute is poised to revolutionize our understanding and treatment of psychiatric and neurological conditions.
  • Dr. Wala commented, “I’m excited to work with BullFrog AI and to apply their novel AI platform in the oncology space.

Pastor aims to use his mental health struggles for good with new children's book

Retrieved on: 
Friday, November 17, 2023
Church, Traders Point Christian Church, Anxiety, Mental health, Bible, Book, Multimedia, Hope, Mixed anxiety–depressive disorder, Amazon, Toy, Nursing, Depression

INDIANAPOLIS, Nov. 17, 2023 /PRNewswire-PRWeb/ -- Indianapolis-area pastor Aaron Hoover will be releasing his second book of the year on November 21, 2023. The book, titled Lord, I Worry, is a beautifully illustrated Christian children's book that helps kids navigate worry while putting their trust in God's promises. It includes a parent guide for worry and Bible references for each of the 13 common childhood worries addressed in the book.

Key Points: 
  • The book, titled Lord, I Worry, is a beautifully illustrated Christian children's book that helps kids navigate worry while putting their trust in God's promises.
  • It includes a parent guide for worry and Bible references for each of the 13 common childhood worries addressed in the book.
  • INDIANAPOLIS, Nov. 17, 2023 /PRNewswire-PRWeb/ -- Indianapolis-area pastor Aaron Hoover will be releasing his second book of the year on November 21, 2023.
  • He wants to help further the conversation about mental health in the Church and help people know they're not alone.

Psychobiotics Industry Analysis 2018-2022 & 2023-2028: Insights Into Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, and Other Applications - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 31, 2023
Mental Health, Food, Beverage, Health, Retail, Pharmaceutical, Depression, Anxiety, DSM-IV codes, Probiotic, Digestion, DuPont, Overalls, COVID-19, GBD, World Health Organization, Bounty, Brain, Inflammation, Tablet, Kerry Group, Grammatical mood, Mixed anxiety–depressive disorder, Alcor Life Extension Foundation, Immune system, Growth, Bacteria, WHO, Biomedical Research & Longevity Society, Sleep, Woman, Global Burden of Disease Study, Psychobiotic, Dietary supplement, Nursing, Pharmaceutical industry, Bifidobacterium, Lactobacillus, Injury, Streptococcus, Lancet, Clostridium

Moreover, the global pandemic triggered by COVID-19 and the subsequent worldwide lockdowns in 2020-2021 have amplified mental health struggles across diverse populations.

Key Points: 
  • Moreover, the global pandemic triggered by COVID-19 and the subsequent worldwide lockdowns in 2020-2021 have amplified mental health struggles across diverse populations.
  • The rise of probiotics as an avenue to address mood disorders, particularly anxiety and depression, marks a significant stride in mental health management.
  • Probiotics, through their interaction with the microbial-gut-brain axis, offer a means to modulate mood and overall health.
  • Market forms include powder, liquid/fluid, tablets, and more, while applications span stress management, mood enhancement, depression, anxiety, sleep disorders, and beyond.

NIH STUDY SUGGESTS MATERNAL INFLAMMATION RISK FACTORS ASSOCIATED WITH CHILDREN'S BEHAVIORAL AND EMOTIONAL REGULATION

Retrieved on: 
Monday, July 17, 2023
Infection, Pregnancy, Depression, University, Education, Anxiety, ECHO, Aggression, Risk, Inflammation, University of Massachusetts Chan Medical School, Bangladesh Technical Education Board, Mother, Overweight, Biophysical environment, Child Behavior Checklist, Mixed anxiety–depressive disorder, Smoking, CBCL, Emotional dysregulation, Nursing, Birth control, MD

DURHAM, N.C., July 17, 2023 /PRNewswire/ -- Maternal inflammation risk factors may be associated with dysregulation in children, according to a study funded by the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health.

Key Points: 
  • DURHAM, N.C., July 17, 2023 /PRNewswire/ -- Maternal inflammation risk factors may be associated with dysregulation in children, according to a study funded by the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health.
  • While inflammation is a normal bodily response to injury or infection, ECHO investigators wanted to learn whether factors linked to inflammation during pregnancy might be associated with dysregulation in children.
  • More youth with dysregulation (35%) were born to mothers with prenatal infections compared with 28% of youth without dysregulation.
  • Other maternal factors studied, including being overweight before pregnancy, attaining less education, and smoking during pregnancy, were associated with higher likelihoods of childhood dysregulation.

ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep

Retrieved on: 
Monday, March 13, 2023
Woman, Diabetes, Self-assessment, Sleep disorder, Pit additive, United Kingdom, Gen, NYSE, Somnolence, ASX, Spotify, Apple, National Sleep Foundation, Risk, Obesity, Mixed anxiety–depressive disorder, Health, RMD, Xerostomia, Silent Generation, Generation Z, Depression, Generator, Patient, Irritability, Sleep, Mental health, Sleep apnea, Consumer Technology Association, SAN, ResMed, Generation X, Sore throat, Pharmaceutical industry, Nursing, Tobacco, Millennials, Baby boomers

8 in 10 respondents reported one or more symptoms of sleep disruption related to sleep quality; Mexico (87%), France (87%), and South Korea (85%) had the highest rates of reported symptoms, while Japan (60%) had the lowest.

Key Points: 
  • 8 in 10 respondents reported one or more symptoms of sleep disruption related to sleep quality; Mexico (87%), France (87%), and South Korea (85%) had the highest rates of reported symptoms, while Japan (60%) had the lowest.
  • 60% of women report being satisfied with their quantity of sleep (the least of any gender), compared to 68% of men and 65% of nonbinary respondents.
  • Additionally, 49% of respondents said their doctor has never asked them proactively about their sleep quality.
  • To learn more about ResMed’s 2023 Global Sleep Survey or to take a quick self-assessment for your risk of sleep apnea, visit SleepForBetterTomorrow.com .

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Additive effect, DSM-IV codes, Drug development, PH94B, Acquisition, SAD, PH10, Depression, Mixed anxiety–depressive disorder, CNS, Anxiety, Social anxiety disorder, MDD, Ajda, Migraine, Central nervous system, Cognition, Hot, Pharmaceutical industry, Pherine

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin).

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin).
  • Vistagen’s acquisition of Pherin eliminates all future royalty payment obligations related to its five pherine nasal spray drug candidates.
  • “This acquisition is another important step in our plan to develop and commercialize PH94B and PH10 as innovative treatments for millions of individuals struggling with anxiety and depression disorders,” stated Shawn Singh, Chief Executive Officer of Vistagen.
  • This acquisition significantly improves the potential future commercial profile of each drug candidate.”
    Additional details regarding the closing of Vistagen’ acquisition of Pherin can be found in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission today and available in the Investors section of Vistagen’s website.

Front Porch Center for Innovation and Wellbeing Launches New Online Resource Focused on Behavioral Health and Wellness

Retrieved on: 
Wednesday, January 11, 2023
Residential Building & Real Estate, Education, Construction & Property, Health, General Health, Seniors, Mental Health, Family, Consumer, Other Education, Telemedicine, Virtual Medicine, Language, COVID, Social, Caregiver, Mental health, Depression, Housing, Anxiety, Death, Dementia, Loneliness, Medicare, Playbook, HUD, Research, Map, CTA, National Institutes of Health, Mixed anxiety–depressive disorder, Degenerative disease, Innovation, Social isolation, Mental, Obesity, NIH, Health insurance, Pharmaceutical industry

The Front Porch Center for Innovation and Wellbeing (FPCIW) announced today that it has launched a new online resource designed to assist affordable senior housing providers establish technology-based behavioral health and wellness programs in their communities.

Key Points: 
  • The Front Porch Center for Innovation and Wellbeing (FPCIW) announced today that it has launched a new online resource designed to assist affordable senior housing providers establish technology-based behavioral health and wellness programs in their communities.
  • The playbook also helps providers assess community-based resources that address behavioral health and wellness and to adapt those resources to best meet their residents’ needs.
  • “The impact of social isolation and loneliness among older adults cannot be overstated,” said Davis Park, vice president of the FPCIW.
  • “We created this playbook to serve as a valuable resource for supporting the mental health and wellbeing needs of underserved older adults.

New Study from Evernow Is Largest to Date to Show Racial and Ethnic Differences in the Experience of Menopause Symptoms

Retrieved on: 
Monday, October 17, 2022
SAN, North American Menopause Society, NCMP, Woman, Science, Menopause, MBA, Research, MPH, Multimedia, Knowledge, Mood Swings, Personal lubricant, Health, Doctor of Philosophy, CEO, Mixed anxiety–depressive disorder, NAMS, Flash, Nightclub, Pharmaceutical industry, Birth control, MD

Key findings include the following:

Key Points: 
  • Key findings include the following:
    Black women were more likely to experience hot flashes, night sweats, vaginal dryness and mood swings.
  • Hispanic women were more likely to report vaginal dryness, mood swings, and anxiety/depression.
  • East Asian women were less likely to report vaginal dryness, mood swings, and heart discomfort.
  • To build a new way of delivering healthcare based on science, innovation, and women's lived experience with menopause.